Targeted Protein Degradation for Neurodegenerative Diseases

Targeted Protein Degradation for Neurodegenerative Diseases

Overview

Targeted Protein Degradation for Neurodegenerative Diseases

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Targeted Protein Degradation for Neurodegenerative Diseases</th>
</tr>
<tr>
<td class="label">Drug</td>
<td>Company</td>
</tr>
<tr>
<td class="label">Arvinas</td>
<td>ARV-110</td>
</tr>
<tr>
<td class="label">Arvinas</td>
<td>ARV-471</td>
</tr>
<tr>
<td class="label">BMS</td>
<td>CC-90009</td>
</tr>
<tr>
<td class="label">Nurix</td>
<td>NX-2127</td>
</tr>
<tr>
<td class="label">Program</td>
<td>Company</td>
</tr>
<tr>
<td class="label">[Tau](/proteins/tau) PROTAC</td>
<td>Arvinas</td>
</tr>
<tr>
<td class="label">Tau molecular glue</td>
<td>Bristol Myers Squibb</td>
</tr>
<tr>
<td class="label">[TDP-43](/mechanisms/tdp-43-proteinopathy) degrader</td>
<td>Various</td>
</tr>
<tr>
<td class="label">Alpha-synuclein degrader</td>
<td>Various</td>
</tr>
<tr>
<td class="label">LRRK2 degrader</td>
<td>Various</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>PROTACs</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Protein</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Degradation</td>
</tr>
<tr>
<td class="label">CNS delivery</td>
<td>Poor</td>
</tr>
<tr>
<td class="label">Dose frequency</td>
<td>Less frequent</td>
</tr>
<tr>
<td class="label">Development stage</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">Cost</td>
<td>Unknown</td>
</tr>
</table>

Targeted protein degradation represents a paradigm shift in drug discovery, offering a novel therapeutic approach that eliminates disease-causing proteins rather than simply inhibiting their function. Using the cell's natural degradation machinery—particularly the [ubiquitin-proteasome system](/mechanisms/ubiquitin-proteasome-system)—degrader molecules can induce the destruction of specific proteins that have been considered "undruggable" by traditional approaches["@bks2022"]. While still in early development for neurodegenerative diseases, this modality has achieved multiple approvals in oncology, validating the platform and generating significant interest for CNS applications.

Mechanism of Action

PROTACs (Proteolysis-Targeting Chimeras)

PROTACs are bifunctional molecules with two distinct binding domains connected by a linker:

The resulting ternary complex brings the target protein into proximity with the E3 ligase, leading to[@paiva2019]:

• Transfer of ubiquitin molecules to the target protein
• Recognition by the proteasome
• Degradation of the target protein

Molecular Glues

Molecular glues are smaller monovalent molecules that:

• Stabilize interactions between a target protein and an E3 ligase
• Induce degradation without bivalent architecture
• Typically have better drug-like properties than PROTACs

Other Approaches

• [Autophagy](/entities/autophagy)-targeting chimeras (AUTAC): Engage autophagy machinery
• Molecular degraders of specific proteins: Optimized for CNS targets
• Hybrid approaches: Combining degradation with other mechanisms

Clinical Programs

Oncology Successes (Proving the Platform)

Neurodegeneration Programs

While still preclinical, several programs are advancing:

Emerging Targets

• Tau: Most advanced CNS degrader program
• Alpha-synuclein: Parkinson's disease target
• TDP-43: ALS and FTD target
• [Huntingtin](/proteins/huntingtin): Huntington's disease target

Advantages

Substoichiometric Activity

• One degrader molecule can eliminate multiple target proteins
• Catalytic mechanism enables potent effects at low concentrations
• May overcome some resistance mechanisms

"Undruggable" Target Access

• Can target proteins without defined binding pockets
• Enzymes, scaffolding proteins, transcription factors
• Proteins resistant to traditional inhibition

Reversible Effects

• Protein levels recover after treatment cessation
• Allows treatment interruption
• Useful for safety assessment

Novel Mechanism of Action

• Different from existing drugs
• May bypass resistance to inhibitors
• Can address gain-of-function toxicities

Limitations

CNS Delivery Challenges

• Large molecular weight (>500 Da) limits [BBB](/entities/blood-brain-barrier) penetration
• Requires specialized brain-penetrant designs
• May require invasive delivery

New Modality Risks

• Limited clinical experience in CNS
• Unexpected toxicities possible
• Long-term consequences unknown

E3 Ligase Dependency

• Limited to E3 ligases with suitable cereblon (CRBN) or VHL binding
• Not all target/ligase combinations work
• May need to identify new E3 ligases

Safety Concerns

• Off-target degradation possible
• Ubiquitin system disruption
• Unknown consequences of chronic degradation

Duration of Effect

• May require continuous dosing
• Drug half-life considerations
• Resistance development possible

Design Considerations

Molecular Weight

• Typical PROTACs: 600-1000+ Da
• Challenge for CNS penetration
• Brain-penetrant designs under development

Linker Optimization

• Length affects ternary complex formation
• Flexibility impacts target engagement
• PEG linkers common

E3 Ligase Selection

• CRBN (cereblon): Most common, thalidomide-derived
• VHL: Well-characterized
• cIAP1: Cancer applications
• CNS-appropriate: Identifying new ligases

Target Selection

• Gain-of-function toxicities ideal
• Knockdown is beneficial
• Scaffolding functions addressable

Future Directions

Brain-Penetrant Degraders

• Reducing molecular weight
• Designing CNS-optimized compounds
• Prodrug approaches

New E3 Ligases

• Identifying ligases with brain expression
• Engineering new ligase binders
• Tissue-specific degradation

Combination Approaches

• Degrader + antibody
• Degrader + ASO
• Multiple degraders

Protein-Specific Advances

• Tau degradation: Most advanced program
• Alpha-synuclein: Significant interest
• TDP-43: Emerging target
• LRRK2: Parkinson's applications

Comparison with Other Modalities

Cross-Links

• [Therapeutic Modalities Overview](/therapeutics/therapeutic-modalities)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Tau Protein](/proteins/tau)
• [Alpha-Synuclein](/proteins/alpha-synuclein)
• [Ubiquitin-Proteasome System](/mechanisms/ubiquitin-proteasome-system)
• [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Lysosomal Calcium Channel Modulation Therapy](/hypothesis/h-8ef34c4c) — <span style="color:#81c784;font-weight:600">0.68</span> · Target: MCOLN1
• [Lysosomal Enzyme Trafficking Correction](/hypothesis/h-b3d6ecc2) — <span style="color:#81c784;font-weight:600">0.65</span> · Target: IGF2R
• [Lysosomal Membrane Repair Enhancement](/hypothesis/h-8986b8af) — <span style="color:#ffd54f;font-weight:600">0.59</span> · Target: CHMP2B
• [Mitochondrial-Lysosomal Contact Site Engineering](/hypothesis/h-0791836f) — <span style="color:#ffd54f;font-weight:600">0.59</span> · Target: RAB7A
• [Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: HCRTR1/HCRTR2
• [Heat Shock Protein 70 Disaggregase Amplification](/hypothesis/h-5dbfd3aa) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: HSPA1A
• [Matrix Stiffness Normalization via Targeted Lysyl Oxidase Inhibition](/hypothesis/h-82922df8) — <span style="color:#81c784;font-weight:600">0.69</span> · Target: LOX/LOXL1-4
• [Targeted APOE4-to-APOE3 Base Editing Therapy](/hypothesis/h-a20e0cbb) — <span style="color:#ffd54f;font-weight:600">0.59</span> · Target: APOE

Related Analyses:

• [TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) &#x1f504;
• [APOE4 structural biology and therapeutic targeting strategies](/analysis/SDA-2026-04-01-gap-010) &#x1f504;
• [Lipid raft composition changes in synaptic neurodegeneration](/analysis/SDA-2026-04-01-gap-lipid-rafts-2026-04-01) &#x1f504;
• [Perivascular spaces and glymphatic clearance failure in AD](/analysis/SDA-2026-04-01-gap-v2-ee5a5023) &#x1f504;